Technology originating at MIT leads to approved bladder cancer treatment
A system conceived in Professor Michael Cima’s lab was approved by the Food and Drug Administration after positive results in patients.
A system conceived in Professor Michael Cima’s lab was approved by the Food and Drug Administration after positive results in patients.
System developed at MIT could provide realistic predictions for a wide variety of reactions, while maintaining real-world physical constraints.
Brushett leads one-of-its-kind program that has been a bridge between education and industry for over a century.
Solubility predictions could make it easier to design and synthesize new drugs, while minimizing the use of more hazardous solvents.
The Initiative for New Manufacturing is convening experts across the Institute to drive a transformation of production across the U.S. and the world.
New microparticles containing iron or iodine could be used to fortify food and beverages, to help fight malnutrition.
Researchers created polymers that are more resistant to tearing by incorporating stress-responsive molecules identified by a machine-learning model.
MIT spinout Tissium recently secured FDA marketing authorization of a biopolymer platform for nerve repair.
The platform identifies, mixes, and tests up to 700 new polymer blends a day for applications like protein stabilization, battery electrolytes, or drug-delivery materials.
The new implant carries a reservoir of glucagon that can be stored under the skin and deployed during an emergency — with no injections needed.
The MIT Energy Initiative’s annual research symposium explores artificial intelligence as both a problem and a solution for the clean energy transition.
Electrodes coated with DNA could enable inexpensive tests with a long shelf-life, which could detect many diseases and be deployed in the doctor’s office or at home.
Eleven faculty members have been granted tenure in six units across MIT’s School of Engineering.
Ranking at the top for the 14th year in a row, the Institute also places first in 11 subject areas.
By delivering an HIV vaccine candidate along with two adjuvants, researchers showed they could generate many more HIV-targeting B cells in mice.